The HCP online learning modules are under maintenance due to upgrades with Flash for the 'Develop' and 'Initiate' modules. We appreciate your patience as we resolve this.

Living with Diabetes? Check out our site for you

Healthcare professional? This is your dedicated site.

You are here

Home » Therapy » Sensor Augmented Pump Therapy

SENSOR AUGMENTED
PUMP THERAPY

SENSOR AUGMENTED
PUMP THERAPY

WHAT IS SENSOR
AUGMENTED PUMP THERAPY?

There are three main components to Sensor Augmented Therapy: a ‘smart’ Insulin Pump, a Continuous Glucose Monitoring (CGM) system and therapy management software. Powered by SmartGuard® technology, the MiniMed® 770G system^ automatically adjusts basal insulin delivery every five minutes, based on continuous glucose monitoring (CGM) readings. This cutting-edge technology helps users reduce burden in managing diabetes and spend more time in range (3.9 mmol/L – 10 mmol/)

HOW TO REDUCE GLYCAEMIC VARIABILITY

MiniMed® 770G reduces both Hypoglycaemia and Hyperglycaemia

MiniMed® 770G with SmartGuardTM technology takes action on behalf of the user, mimicking some functions of a healthy pancreas to deliver advanced glucose control. SmartGuardTM Auto Mode is designed to determine an individual’s insulin needs and to take action to minimise both high and low glucose levels in order to spend more time in target range.

The Guardian™ Sensor 3 sits under the skin in the interstitial fluid, where cells get oxygen and nutrients, including glucose.

The Insulin Pump acts as the receiver of the CGM data sent wirelessly from the sensor by the transmitter.

  • SmartGuardTM Technology requires minimal input – patients need to enter mealtime carbohydrates,accept Bolus™ correction recommendations, and periodically calibrate the sensor.
  • The glucose sensor should avoid recent infusion sites and should be worn according to:
  • The patient’s desired comfort level
  • Individual preference
  • The patient’s experience.
Night 1
Night 2
Night 3
Night 4

 

Benefits of CGM

What are the benefits of CGM?

CGM improves time in range and glycaemic control. Several randomised controlled trials12,17,18 showed that CGM can lead to:

  • Reduced glycaemic variability - an average of 72% Time in Range20
  • Up to 27% less time in high range20
  • A 98% improvement in HbA1c when compared to MDI20
  • Greater number of patients reaching the HbA1c target recommended by the American Diabetes Association (ADA)

All of these benefits can help patients achieve better control over diabetes.

The advantages of CGM over traditional fingerstick testing and HbA1c testing are well documented
Research has shown that:

  • 60% of glucose lows may not be revealed with fingerstick testing alone19
  • CGM can significantly reduce HbA1c and has been shown to reduce HbA1c levels by up to 1% when compared with fingerstick testing alone12

How your patients can benefit

CGM can be very beneficial, especially for parents and people with a busy lifestyle.

  • Parents can have greater peace of mind, knowing they not only have a system that can automatically suspend highs or lows through the day, but they can also view levels directly on their smartphone using the CareLink Connect App
  • Sports enthusiasts and students can concentrate on competing or taking their exams

Discover whether your patient is eligible for funding from the CGM Initiative.

Learn more

12. Bergenstal RM, Tamborlane WV, Ahmann A, et al. The STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in Insulin Dependent Diabetes. N Engl J Med. 2010;363(4):311-320.

17. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464-1476.

18. Raccah D, Sulmont V, Resnik Y,et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend Study. Diabetes Care. 2009;32(12):2245-2250.

19. Kaufman FR, et al. A pilot study of continuous glucose monitoring system. Diab Care. 2001:24:2030-2034 2. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of Sensor-Augmented Insulin Pump Therapy in Insulin Dependent Diabetes NEJM. 2010;363(4):311-320.

20. Data on File.

^Components sold separately. Automated insulin delivery is made possible through combining Medtronic insulin pump and continuous glucose monitoring technology. 

YOU MAY BE INTERESTED IN

MINIMED® 670G INSULIN PUMP SYSTEM^

Discover better diabetes control for your patients.

VIEW IT HERE
CONTINUOUS GLUCOSE MONITORING

CONTINUOUS GLUCOSE MONITORING

CGM technology enables your patients to monitor their glucose levels 24/7.

VIEW IT HERE

MiniMed® 670G System Pivotal study

A Prospective before and after Multi-centre study assessing SmartGuard® Auto Mode vs Manual Mode (SAP) in adolescents(n= 30)and adults(n=94) with Type 1 Diabetes over 3 months.

VIEW IT HERE
MiniMed® 670G system update

WEBINAR: MiniMed® 670G system update by Fran Kaufman

Dr. Fran Kaufman lecture on the system update and key learning of the Minimed 670G system.

VIEW IT HERE